SANTA MONICA, CA, Nov. 30, 2016 /PRNewswire/ - The Company's flagship therapy to treat prostate cancer, ProscaVax, is to enter into Phase II testing by the end of 2016. More than 220,00 new cases of prostate cancer are diagnosed annually. The market for therapies targeting the disease is estimated at over $7.1 Billion. Read full report below.
Legal Disclaimer: Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release.
SOURCE Online Media Group Inc